

10/586288

EXPRESS MAIL 13 JUL 2006

Express Mail No. EV668295097US

Date of Deposit: July 13, 2006

PATENT

SLR:dm 07/12/06 4239-66342-08 553731 E-282-2003/0-US-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Dogulu et al.

**Application No.** \_\_\_\_\_

**Filed:** Herewith

**Confirmation No.** \_\_\_\_\_

**For:** METHOD EVOLVED FOR  
RECOGNITION OF THROMBOPHILIA  
(MERT)

**Examiner:** Not yet assigned

**Art Unit:** Not yet assigned

**Attorney Reference No.** 4239-66342-08

MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(b)(2)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents and two non-English-language documents. The relevance of the non-English language documents may be ascertained from the English-language abstracts attached to the documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

10/586288  
APC Rec'd PCT/TO 13 JUL 2006

Express Mail No. EV668295097US

Date of Deposit: July 13, 2006

PATENT

SLR:dm 07/12/06 4239-66342-08 553731 E-282-2003/0-US-03

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.


The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

  
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

cc: Docketing

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	4239-66342-08
	Application Number	10/586288
	Filing Date	July 13, 2006
	First Named Inventor	Dogulu
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

**U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		2002/0106657 A1	08/08/2002	Taylor et al.
		2003/0073122 A1	04/17/2003	Sosnowski et al.
		2003/0099958 A1	05/29/2003	McCarthy
		6,303,301	10/16/2001	Mack
		6,342,355	01/29/2002	Hacia et al.
		6,368,799	04/09/2002	Chee
		6,410,229	06/25/2002	Lockhart et al.
		6,525,185	02/25/2003	Fan et al.

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Germany	DE 102 37 073 A1	02/19/2004	OGHAM GmbH

**OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Bauer et al., "Prothrombin Activation is Increased Among Asymptomatic Carriers of the Prothrombin G20210A and Factor V Arg506Gln Mutations," <i>Thromb. Haemost.</i> 84:396-400 (2000).
		Buchholz et al., "Inherited Thrombophilia: Impact on Human Reproduction," <i>AJRI</i> 50:20-32 (2003).

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	------------------

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66342-08
Application Number	22/586288
Filing Date	July 13, 2006
First Named Inventor	Dogulu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Erali et al., "Evaluation of Electronic Microarrays for Genotyping Factor V, Factor II, and MTHFR," <i>Clin. Chem.</i> 49:732-739 (2003).
		Evans et al., "Determination of the Factor V Leiden Single-Nucleotide Polymorphism in a Commercial Clinical Laboratory by Use of NanoChip Microelectronic Array Technology," <i>Clin. Chem.</i> 48:1406-1411 (2002).
		Franco et al., "Genetic Risk Factors of Venous Thrombosis," <i>Hum. Genet.</i> 109:369-384 (2001).
		Franco et al., "Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease," <i>Curr. Genomics</i> 4:309-336 (2003).
		González-Ordóñez, "Bases Genéticas de la Enfermedad Tromboembólica Venosa," <i>Química Clínica</i> 22:367-381 (2003).
		Grody, "Molecular Genetic Risk Screening," <i>Annu. Rev. Med.</i> 54:473-490 (2003).
		Harrington et al., "Genetic Variations Observed in Arterial and Venous Thromboembolism—Relevance for Therapy, Risk Prevention and Prognosis," <i>Clin. Chem. Lab. Med.</i> 41:496-500 (2003).
		Holtzman et al., "Predictive Genetic Testing: From Basic Research to Clinical Practice," <i>Science</i> 278:602-605 (1997).
		Kottke-Marchant, "Genetic Polymorphisms Associated With Venous and Arterial Thrombosis," <i>Arch. Pathol. Lab. Med.</i> 126:295-304 (2002).
		Li et al., "Genetic Risk Factors of Vascular Thrombotic Disease in Taiwan," <i>Acta Cardiol. Sin.</i> 16:197-208 (2000).
		Pecheniuk, et al., "DNA Technology for the Detection of Common Genetic Variants that Predispose to Thrombophilia," <i>Blood Coagul. Fibrinolysis</i> 11:683-700 (2000).
		Pollak et al., "Microarray-Based Genetic Analyses for Studying Susceptibility to Arterial and Venous Thrombotic Disorders," <i>Ital. Heart J.</i> 2:568-572 (2001).
		Randi et al., "Identification of Differentially Expressed Genes in Coronary Atherosclerotic Plaques from Patients with Stable or Unstable Angina by cDNA Array Analysis," <i>J. Thromb. Haemost.</i> 1: 829-835 (2003).
		Schrijver et al., "Diagnostic Single Nucleotide Polymorphism Analysis of Factor V Leiden and Prothrombin 20210G>A," <i>Am. J. Clin. Pathol.</i> 119:490-496 (2003).
		Zhong et al. "Single-Nucleotide Polymorphism Genotyping on Optical Thin-Film Biosensor Chips," <i>PNAS</i> 100:11559-11564 (2003).

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	